Hans-peter Hartung
Professor and Chairman
Department of Neurology
GeNeuro
Switzerland
Biography
Professor Hartung received his undergraduate training at the Universities of Düsseldorf, Glasgow, Oxford and London. After graduation as MD in 1980 he served an immunology fellowship at the University of Mainz. He started his career in neurology at the University of Düsseldorf, where he became assistant professor in 1987. He was appointed professor and head of the MS clinical research group at the University of Würzburg in 1990 and moved in 1997 to Graz, Austria, to become chairman of the University Department of Neurology. He is currently chair of the Department of Neurology at Heinrich Heine University Düsseldorf, a position he has held since 2001, and since 2013 director of the Center for Neuropsychiatry. He is in charge of two busy inpatient departments with a total of 100 beds including stroke unit. Professor Hartung’s clinical and translational research interests are in the field of basic and clinical neuroimmunology and in particular multiple sclerosis and immune neuropathies. He has authored or co-authored more than 900 articles in peer-reviewed journals, one hundred book chapters and edited nine books. He oversees the various research activities (clinical and preclinical) in his department that relate to Parkinson`s and movement disorders incl deep brain stimulation, stroke, neuromuscular disorders, neuro-HIV and infectious diseases, spinal cord injury, repair strategies in CNS and PNS. He has been involved as member of the Steering Committee in numerous international multicentre therapeutic phase 2 and 3 trials in multiple sclerosis, Guillain-Barré Syndrome and CIDP.
Research Interest
Pathogenesis of autoimmune diseases of the central and peripheral nervous system (MS, GBS, CIDP) and their animal models and design and exploration of experimental therapies. Development of regenerative therapies for inflammatory, ischemic and traumatic insults to the nervous system. Development of new immunomodulatory therapies for MS, GBS, CIDP and identification of biomarkers of diease activity, prognosis, therapeutic response.
